Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01776060 |
Recruitment Status
:
Active, not recruiting
First Posted
: January 25, 2013
Last Update Posted
: February 12, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Primary Progressive Multiple Sclerosis | Other: generation of 'omic markers of disease progression |
Unlike Relapsing Remitting Multiple Sclerosis (RRMS) or Secondary Progressive Multiple Sclerosis (SPMS) in which patients experience a remission or lessening of their symptoms, Primary Progressive Multiple Sclerosis (PPMS) is characterized by progression of disability from onset, with no, or only occasional and minor, remissions and improvements. The age of onset for the primary progressive subtype is later than for the relapsing-remitting, but similar to mean the age of progression between the relapsing-remitting and the secondary progressive - around 40 years of age. Because of its prevalence, RRMS represents the largest basis for basic and clinical MS research. Therefore, drugs have primarily been developed to slow disease progression in RRMS and SPMS patients. No treatment has been proven successful in treating primary progressive MS.
The MURDOCK-MS collection represents a unique opportunity to carry out detailed biomarker research on PPMS patients and, to the knowledge of this investigator and his colleagues in the field, would represent an exceptional cohort that is not available elsewhere in the US or the rest of the world. Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression. This progressive etiology would provide valuable insight into PPMS development and may also shed light on SPMS progression.
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Other |
Official Title: | Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study |
Study Start Date : | January 2013 |
Estimated Primary Completion Date : | February 2020 |
Estimated Study Completion Date : | February 2020 |

-
Other: generation of 'omic markers of disease progression
- Generation of 'omic markers of disease progression [ Time Frame: 5 years ]Biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression. This progressive etiology would provide valuable insight into PPMS development and may also shed light on SPMS progression.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Enrolled in the MURDOCK Study Horizon 1.5 (Pro00011196)
- Enrolled in the Multiple Sclerosis Cohort (Pro00023791)
- Diagnosed with Primary Progressive Multiple Sclerosis
- At least 18 years of age
Exclusion Criteria:
- Participants not willing to participate or sign informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01776060
United States, North Carolina | |
NE Neurology | |
Concord, North Carolina, United States, 28025 | |
The Stedman Center on the Duke Center for Living Campus | |
Durham, North Carolina, United States, 27705 | |
Raleigh Neurology Associates | |
Raleigh, North Carolina, United States, 27607 |
Principal Investigator: | Simon Gr, PhD | Duke Medicine Site Based Research Group |
Additional Information:
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT01776060 History of Changes |
Other Study ID Numbers: |
Pro00040961 |
First Posted: | January 25, 2013 Key Record Dates |
Last Update Posted: | February 12, 2018 |
Last Verified: | February 2018 |
Keywords provided by Duke University:
Primary Progressive Multiple Sclerosis Multiple Sclerosis biomarker 'omic progression |
Additional relevant MeSH terms:
Sclerosis Multiple Sclerosis Multiple Sclerosis, Chronic Progressive Pathologic Processes Demyelinating Autoimmune Diseases, CNS |
Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |